These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32182145)

  • 41. Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch.
    Ameri M; Ao Y; Lewis H
    AAPS PharmSciTech; 2021 Jun; 22(5):175. PubMed ID: 34114100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
    Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
    J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a thermostable microneedle patch for influenza vaccination.
    Mistilis MJ; Bommarius AS; Prausnitz MR
    J Pharm Sci; 2015 Feb; 104(2):740-9. PubMed ID: 25448542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, characterization, and modeling of a chitosan microneedle patch for transdermal delivery of meloxicam as a pain management strategy for use in cattle.
    Castilla-Casadiego DA; Carlton H; Gonzalez-Nino D; Miranda-Muñoz KA; Daneshpour R; Huitink D; Prinz G; Powell J; Greenlee L; Almodovar J
    Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111544. PubMed ID: 33255096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
    Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
    Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines.
    An M; Liu H
    Small; 2017 Jul; 13(26):. PubMed ID: 28544329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microneedle-Mediated Vaccination: Innovation and Translation.
    Sheng T; Luo B; Zhang W; Ge X; Yu J; Zhang Y; Gu Z
    Adv Drug Deliv Rev; 2021 Dec; 179():113919. PubMed ID: 34375682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.
    Lanza JS; Vucen S; Flynn O; Donadei A; Cojean S; Loiseau PM; Fernandes APSM; Frézard F; Moore AC
    Int J Pharm; 2020 Aug; 586():119390. PubMed ID: 32540349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. M cell targeting engineered biomaterials for effective vaccination.
    Islam MA; Firdous J; Badruddoza AZM; Reesor E; Azad M; Hasan A; Lim M; Cao W; Guillemette S; Cho CS
    Biomaterials; 2019 Feb; 192():75-94. PubMed ID: 30439573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.
    Al-Zahrani S; Zaric M; McCrudden C; Scott C; Kissenpfennig A; Donnelly RF
    Expert Opin Drug Deliv; 2012 May; 9(5):541-50. PubMed ID: 22475249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.
    Baker B; Hacker E; Siller G; Lee M; Mursaliyev N; Forster A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2189409. PubMed ID: 36949009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innate local response and tissue recovery following application of high density microarray patches to human skin.
    Muller DA; Henricson J; Baker SB; Togö T; Jayashi Flores CM; Lemaire PA; Forster A; Anderson CD
    Sci Rep; 2020 Oct; 10(1):18468. PubMed ID: 33116241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs.
    Bernelin-Cottet C; Urien C; McCaffrey J; Collins D; Donadei A; McDaid D; Jakob V; Barnier-Quer C; Collin N; Bouguyon E; Bordet E; Barc C; Boulesteix O; Leplat JJ; Blanc F; Contreras V; Bertho N; Moore AC; Schwartz-Cornil I
    J Control Release; 2019 Aug; 308():14-28. PubMed ID: 31265882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nasal vaccine innovation.
    Jabbal-Gill I
    J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies.
    Shalaby WS
    Clin Immunol Immunopathol; 1995 Feb; 74(2):127-34. PubMed ID: 7828366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.
    Quan FS; Kim YC; Yoo DG; Compans RW; Prausnitz MR; Kang SM
    PLoS One; 2009 Sep; 4(9):e7152. PubMed ID: 19779615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Smart Responsive Microarray Patches for Transdermal Drug Delivery and Biological Monitoring.
    Zhao L; Zhang C; Abu-Ershaid JM; Li M; Li Y; Naser Y; Dai X; Abbate MTA; Donnelly RF
    Adv Healthc Mater; 2021 Oct; 10(20):e2100996. PubMed ID: 34449129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term stability of influenza vaccine in a dissolving microneedle patch.
    Mistilis MJ; Joyce JC; Esser ES; Skountzou I; Compans RW; Bommarius AS; Prausnitz MR
    Drug Deliv Transl Res; 2017 Apr; 7(2):195-205. PubMed ID: 26926241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fabrication and characterization of matrix type transdermal patches loaded with tizanidine hydrochloride: potential sustained release delivery system.
    Shahid N; Siddique MI; Razzaq Z; Katas H; Waqas MK; Rahman KU
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2061-2070. PubMed ID: 30081679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.